2-<4-Methylmercapto-phenoxy>-aethanol-(1) | 43199-00-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-<4-Methylmercapto-phenoxy>-aethanol-(1)
• 英文别名: 2-(4-Methylmercapto-phenoxy)-aethanol-(1)；2-[4-(Methylthio)phenoxy]ethanol；2-(4-methylsulfanylphenoxy)ethanol
• CAS: 43199-00-4
• 化学式: C₉H₁₂O₂S
• 分子量: 184.259
• InChiKey: CIGKXQGMJPHOIE-UHFFFAOYSA-N

物化性质

• 熔点：
  55-56 °C
• 沸点：
  325.8±22.0 °C(Predicted)
• 密度：
  1.17±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  54.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-<4-Methylmercapto-phenoxy>-aethanol-(1) 在 吡啶 、 双氧水 、 对甲苯磺酰氯 、 sodium iodide 作用下， 以 溶剂黄146 、 丙酮 为溶剂， 生成 4-(2-Diaethylaminoaethoxy)phenyl-methyl-sulfoxid
  参考文献：
  名称：

  一些芳氧基烷基胺，N-芳基乙二胺和相关化合物作为厌食剂。

  摘要：

  DOI：

  10.1021/jm00291a015
• 作为产物：
  描述：

  4-(甲硫基)苯酚 、 2-氯乙醇 在 sodium hydroxide 作用下， 生成 2-<4-Methylmercapto-phenoxy>-aethanol-(1)
  参考文献：
  名称：

  单胺氧化酶抑制剂。一系列取代的烷基肼的合成与评估。

  摘要：

  DOI：

  10.1021/jm00337a015

文献信息

• Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound
  申请人：Eisai Co., Ltd.

  公开号：US20040220193A1

  公开（公告）日：2004-11-04

  The present invention provides a novel compound having a superior calcium antagonism, in particular, a neuron-selective calcium antagonism. Namely, it provides a compound represented by the following formula, a salt thereof or a hydrate of them. 1 In the formula, Ar indicates an optionally substituted 5- to 14-membered aromatic ring etc.; the ring A indicates any one ring selected from a piperazine, a homopiperazine, a piperidine and the like; the ring B indicates an optionally substituted C 3-14 hydrocarbon ring etc.; E indicates a single bond, a group represented by the formula —CO—, etc.; X indicates a single bond, an oxygen atom etc.; R 1 indicates a hydrogen atom, a halogen atom, a hydroxyl group etc.; and D 1 , D 2 , W 1 and W 2 are the same as or different from each other and each represents a single bond or an optionally substituted C 1-6 alkylene chain.

  本发明提供了一种具有卓越的钙拮抗作用，特别是神经元选择性钙拮抗作用的新化合物。即，提供了下式所示的化合物、其盐或水合物。其中，Ar表示可选取的5-至14-成员芳香环等；环A表示选自哌嗪、同哌嗪、吡啶等任意一环；环B表示可选取的C3-14碳氢环等；E表示单键、由公式—CO—表示的基团等；X表示单键、氧原子等；R1表示氢原子、卤原子、羟基等；D1、D2、W1和W2相同或不同，每个代表单键或可选取的C1-6烷基链。
• N-(Aryloxyalkyl)-N'-(aminoalkyl)thioureas
  申请人：A. H. Robins Company, Incorporated

  公开号：US04558155A1

  公开（公告）日：1985-12-10

  N-(Aryloxyalkyl)-N'-(aminoalkyl)ureas and thioureas having the formula: ##STR1## wherein R.sup.1 and R.sup.2 are hydrogen, loweralkyl, cycloalkyl, phenyl or phenyllower alkyl, and R.sup.3 and R.sup.4 are hydrogen, loweralkyl, phenyl and phenylalkyl or R.sup.3 and R.sup.4 taken together with the adjacent nitrogen form a heterocyclic residue are disclosed in a method of suppressing cardiac arrhythmias.

  本发明涉及一种抑制心律失常的方法，其中抑制剂为具有以下式子的N-(芳氧基烷基)-N'-(氨基烷基)脲和硫脲：##STR1## 其中R.sup.1和R.sup.2是氢、低碳基、环烷基、苯基或苯基低碳基，R.sup.3和R.sup.4是氢、低碳基、苯基和苯基烷基或R.sup.3和R.sup.4与相邻的氮一起形成杂环残基。
• N-(aryl-,aryloxy-,arylthio-arylsulfinyl-and arylsulfonyl-)alkyl-N,N'-(or
  申请人：A. H. Robins Company, Incorporated

  公开号：US04895840A1

  公开（公告）日：1990-01-23

  Novel N-(Aryl-,aryloxy-,arylthio-,arylsulfinyl-and arylsulfonyl-)alkyl-N,N'-(or N',N')alkylaminoalkyl ureas, thioureas and cyanoguanidines represented by the following formula: ##STR1## wherein Ar is aryl selected from the group consisting of 1- and 2-naphthyl, 2,3-dihydro-1H-inden-4(or 5)-yl,2-furanylmethyl,2-pyridinyl, phenyl and phenyl substituted by 1-3 radicals commonly used in the pharmaceutical art; (X).sub.d is oxygen, thio, sulfinyl, sulfonyl or d is zero; Z and W are each R or-(CH.sub.2).sub.m -NR.sup.1 R.sup.2 wtih the proviso that when Z is R, W is-(CH.sub.2).sub.m -NR.sup.1 R.sup.2 and when Z is-(CH.sub.2).sub.m -NR.sup.1 R.sup.2, W is R; B is carbonyl, thioxomethyl, or cyanoiminomethyl; R, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are selected from the group consisting of hydrogen, loweralkyl, cycloalkyl, phenyl or phenyl-loweralkyl wherein phenyl may be substituted by 1-3 radicals commonly used in the pharmaceutical art; R.sup.1 and R.sup.2, and R.sup.3 and R.sup.4 may together with the adjacent nitrogen form the heterocyclic ring structure 1-homopiperidinyl, 4-morpholinyl, 1-piperazinyl, 4-substituted-1-piperazinyl, 1-pyrrolidinyl or 1-piperidinyl and the pharmaceutically acceptable salts thereof are disclosed. A pharmaceutical method for administering the compounds for their cardiac antiarrhythmic effect and pharmaceutical compositions for the treatment of cardiac arrhythmia are also disclosed.

  以下公式所代表的小说N-（芳基，芳氧基，芳硫基，芳基磺酰基和芳基亚磺酰基）-烷基-N，N' -（或N'，N'）烷基氨基烷基脲，硫脲和氰脲：##STR1## 其中Ar是从1-和2-萘基，2,3-二氢-1H-茚-4（或5）-基，2-呋喃甲基，2-吡啶基，苯基和苯基取代物中选择的芳基；（X）.sub.d是氧，硫，亚磺酰基，磺酰基或d为零；Z和W分别为R或-（CH.sub.2）.sub.m-NR.sup.1R.sup.2，但是当Z为R时，W为-（CH.sub.2）.sub.m-NR.sup.1R.sup.2，当Z为-（CH.sub.2）.sub.m-NR.sup.1R.sup.2时，W为R；B是羰基，硫代甲基或氰基亚甲基；R，R.sup.1，R.sup.2，R.sup.3和R.sup.4从氢，低碳基，环烷基，苯基或苯基-低碳基中选择，其中苯基可以被常用于制药的1-3个基团取代；R.sup.1和R.sup.2，R.sup.3和R.sup.4可以与相邻的氮一起形成杂环环结构1-同源哌啶基，4-吗啉基，1-哌嗪基，4-取代-1-哌嗪基，1-吡咯基或1-哌啶基及其制药可接受的盐。还公开了一种用于治疗心脏抗心律失常作用的化合物的药物方法以及用于治疗心脏心律失常的制药组合物。
• Derivatives of alkylaminoalkyl ureas and cyanoguanidines
  申请人：A.H. ROBINS COMPANY, INCORPORATED

  公开号：EP0295010A1

  公开（公告）日：1988-12-14

  Compounds of general formula I wherein, Ar represents a 1-naphthyl group, a 2-naphthyl group, a 2,3-dihydro-1 H-inden-4(or 5)-yl group, a 2-furanylmethyl group, a 2-pyridinyl group, a phenyl group or a phenyl substituted by one to three substituents wherein the or each substituent independently represents a loweralkyl group, a loweralkoxy group, a diloweralkylamino group, a cyano group, a loweralkylthio group, a loweralkylsulfinyl group, a loweralkylsulfonyl group, an acyl group, an acylamino group, an aminocarbonyl group, a diloweral- kylaminoloweralkoxy group, a trifluoromethyl group, a nitro group or a halogen atom; X represents a thio group, a sulfinyl group, a sulfonyl group or an oxygen atom; d represents zero or one; B represents a carbonyl group, a thioxomethyl group or a cyanoiminomethyl group; each of n, m and p independently represents an integer from 2 to 6 inclusive; each of Z and W independently represent an R group or a group with the proviso that when Z represents R, W represents a -(CH2)m-NR1R2 group and when Z represents (CH2)m-NR1R2, W represents R; each of R, R1, R2, R3 and R4 independently represents a hydrogen atom, a loweralkyl group, a cycloalkyl group, a phenyl group or a phenylloweralkyl group wherein phenyl may be substituted by one to three radicals wherein each radical independently represents a loweralkyl group, a loweralkoxy group, a cyano group, a trifluoromethyl group, a nitro group or a halogen atom or each of R1 and R2, and R3 and R4 may, together with the adjacent nitrogen atom form the heterocyclic ring structure 1-homopiperidinyl, 1-piperidinyl, 4-morpholinyl, 1-pyrrolidinyl, 1-piperazinyl, or 4-substituted-1-piperazinyl; with the further proviso that some meanings given for the symbols must not be realized simultaneously, as indicated specifically in claim 1, or the pharmaceutically acceptable salts thereof are useful in the treatment of cardiac arrhythmia.

  通式 I 的化合物 其中 Ar 代表 1-萘基、2-萘基、2,3-二氢-1 H-茚-4（或 5）-基、2-呋喃甲基、2-吡啶基、苯基或被一至三个取代基取代的苯基，其中或每个取代基独立地代表低级烷基、一个低级烷氧基、一个低级烷氨基、一个氰基、一个低级烷硫基、一个低级烷基亚磺基、一个低级烷基磺酰基、一个酰基、一个酰氨基、一个氨基羰基、一个低级烷氨基低级烷氧基、一个三氟甲基、一个硝基或一个卤原子； X 代表硫代基团、亚砜基团、磺酰基团或氧原子； d 代表 0 或 1； B 代表羰基、硫氧甲基或氰亚氨基甲基； n、m 和 p 各自独立地代表 2 至 6（含 6）的整数 Z和W各自独立地代表一个R基团或一个 但当 Z 代表 R 时，W 代表-(CH2)m-NR1R2 基团；当 Z 代表 (CH2)m-NR1R2 时，W 代表 R； R、R1、R2、R3 和 R4 各自独立地代表氢原子、低级烷基、环烷基、苯基或苯基低级烷基，其中苯基可被一至三个基团取代，每个基团独立地代表低级烷基、低级烷氧基、氰基、三氟甲基、硝基或卤素原子或 R1 和 R2 以及 R3 和 R4 中的每一个可与相邻的氮原子一起形成杂环结构 1-高哌啶基、1-哌啶基、4-吗啉基、1-吡咯烷基、1-哌嗪基或 4-取代-1-哌嗪基； 进一步的但书是，如权利要求 1 中特别指出的，符号的某些含义不得同时实现，或其药学上可接受的盐类可用于治疗心律失常。
• Nitrogen-containing heterocyclic compounds and pharmaceutical composition containing the compounds
  申请人：Eisai R&D Management Co., Ltd.

  公开号：EP1818326A1

  公开（公告）日：2007-08-15

  The present invention provides a novel compound having a superior calcium antagonism, in particular, a neuron-selective calcium antagonism. Namely, it provides a compound represented by the following formula (I), a salt thereof or a hydrate of them: wherein Ar is a thiophene or benzene ring which may be substituted,the ring A is a piperazine ring, homopiperazine ring or piperidine ring which may be substituted, the ring B is a C6-14 aromatic hydrocarbon ring or 5- to 14-membered aromatic heterocyclic ring which may be substituted, the partial structure -D1-E-D2- is a C1-4 alkylene group, W1 and W2 are the same as or different from each other and each represents (1) a single bond or (2) a C1-6 alkylene chain which may be substituted, X is (1) an oxygen atom, a group represented by (2) the formula -NR2- (wherein R2 indicates a hydrogen atom, or a C1-6 alkyl group, a C3-8 cycloalkyl group, a lower acyl group or a C1-6 alkylsulfonyl group which may be substituted) or (3) -NH-SO2-, R1 is a methyl group, an ethyl group, a n-propyl group or an isopropyl group.

  本发明提供了一种新型化合物，它具有优异的钙拮抗作用，尤其是神经元选择性钙拮抗作用。也就是说，本发明提供了由下式（I）代表的化合物、其盐或它们的水合物： 其中 Ar 是可被取代的噻吩环或苯环，环 A 是可被取代的哌嗪环、均哌嗪环或哌啶环，环 B 是可被取代的 C6-14 芳烃环或 5-14 元芳香杂环，部分结构 -D1-E-D2- 是 C1-4 烯基、W1和W2彼此相同或不同，各自代表(1)单键或(2)可被取代的C1-6亚烷基链，X是(1)氧原子、由(2)式-NR2-（其中R2表示氢原子）代表的基团或C1-6烷基、或 C1-6 烷基、C3-8 环烷基、低级酰基或可能被取代的 C1-6 烷基磺酰基）或 (3) -NH-SO2- 所代表的基团，R1 是甲基、乙基、正丙基或异丙基。